Aduro Biotech Company Profile (NASDAQ:ADRO)

About Aduro Biotech (NASDAQ:ADRO)

Aduro Biotech logoAduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADRO
  • CUSIP: N/A
  • Web:
  • Market Cap: $688.3 million
  • Outstanding Shares: 74,612,000
Average Prices:
  • 50 Day Moving Avg: $10.84
  • 200 Day Moving Avg: $10.89
  • 52 Week Range: $8.75 - $15.53
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.26
  • P/E Growth: 0.060
Sales & Book Value:
  • Annual Revenue: $17.36 million
  • Price / Sales: 39.65
  • Book Value: $3.50 per share
  • Price / Book: 2.64
  • EBITDA: ($94,740,000.00)
  • Net Margins: -609.58%
  • Return on Equity: -43.92%
  • Return on Assets: -23.46%
  • Current Ratio: 13.33%
  • Quick Ratio: 13.33%
  • Average Volume: 403,074 shs.
  • Beta: 3.58
  • Short Ratio: 17.19

Frequently Asked Questions for Aduro Biotech (NASDAQ:ADRO)

What is Aduro Biotech's stock symbol?

Aduro Biotech trades on the NASDAQ under the ticker symbol "ADRO."

How were Aduro Biotech's earnings last quarter?

Aduro Biotech, Inc. (NASDAQ:ADRO) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.02. The company earned $5.90 million during the quarter, compared to the consensus estimate of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The company's revenue for the quarter was down 84.9% compared to the same quarter last year. During the same period last year, the firm posted $0.03 EPS. View Aduro Biotech's Earnings History.

Where is Aduro Biotech's stock going? Where will Aduro Biotech's stock price be in 2017?

8 brokers have issued 12-month target prices for Aduro Biotech's shares. Their predictions range from $14.00 to $30.00. On average, they anticipate Aduro Biotech's share price to reach $20.00 in the next twelve months. View Analyst Ratings for Aduro Biotech.

What are analysts saying about Aduro Biotech stock?

Here are some recent quotes from research analysts about Aduro Biotech stock:

  • 1. According to Zacks Investment Research, "Aduro’s lead candidate, CRS-207, being evaluated for a number of cancer indications, bodes well for long-term growth. Moreover, its collaboration agreements with large pharma companies, Novartis, Johnson & Johnson and Incyte are big positives for the company. Aduro has a broad and a promising pipeline of novel immunotherapies under development for the treatment of a variety of cancers. Aduro’s efforts to develop its pipeline are encouraging. However, Aduro depends largely on funds generated from collaboration and license agreements, government grants and other payments for the development of its pipeline candidates. Thus, inability to secure sufficient funding could hinder its pipeline progress. Aduro’s shares underperformed the industry in the last one year. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters." (8/2/2017)
  • 2. Canaccord Genuity analysts commented, "1Q17 results recap. Adjusted non-GAAP revenue (excluding the individual commercial business) grew 4.4% year over year. Adjusted MLR was 85.2% compared to 85.0% a year ago. MLR benefitted from the exit of certain Medicare markets, which was offset to some degree by lower prior period development when compared to a year ago. Cost trends appear to be in check, consistent with other publicly-traded health insurers." (5/3/2017)
  • 3. FBR & Co analysts commented, "Aduro Biotech, Inc.’s (ADRO) cancer immunotherapy platform triggers both innate and adaptive immunity, resulting in a broad and potent multi-pronged immune response. The company’s engineered live, attenuated, double-deleted (LADD) Listeria monocytogenes program is capable of inducing an antigen-specific adaptive T-cell response (CD8+ and CD4+), as well as an innate immune response that includes cytokines, chemokines, gamma delta T cells, and NK cells. The company’s STING (Stimulator of Interferon Genes, driven by cytosolic DNA) platform induces dendritic cells and enhances an anti-tumor T-cell response in the tumor microenvironment. Aduro’s third technology platform is B-select, based on clonal expansion of B cells producing highly selective and functional antibodies against targets that regulate the immune response. Given that the future of cancer immunotherapy points to combinations, Aduro’s programs are complementary combination approaches that activate distinct mechanisms of actions that could be synergistic." (3/7/2017)

Who are some of Aduro Biotech's key competitors?

Who are Aduro Biotech's key executives?

Aduro Biotech's management team includes the folowing people:

  • Stephen T. Isaacs, Chairman of the Board, President and Chief Executive Officer
  • Gregory W. Schafer, Chief Operating Officer
  • Blaine Templeman, Executive Vice President, General Counsel, Secretary
  • Dirk G. Brockstedt, Executive Vice President of Research and Development
  • Jennifer Lew CPA, Senior Vice President - Finance
  • Andrea van Elsas Ph.D., Chief Scientific Officer
  • Natalie R. Sacks, Chief Medical Officer
  • Stephanie Monaghan O'Brien J.D., Lead Independent Director
  • Gerald Chan Ph.D., Independent Director
  • William M. Greenman, Independent Director

When did Aduro Biotech IPO?

(ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who owns Aduro Biotech stock?

Aduro Biotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include MORNINGSIDE VENTURE (VI) INVESTMENTS LTD (12.47%). Company insiders that own Aduro Biotech stock include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro Biotech.

How do I buy Aduro Biotech stock?

Shares of Aduro Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aduro Biotech's stock price today?

One share of Aduro Biotech stock can currently be purchased for approximately $9.23.

MarketBeat Community Rating for Aduro Biotech (NASDAQ ADRO)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about Aduro Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aduro Biotech (NASDAQ:ADRO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.00 (116.80% upside)
Consensus Price Target History for Aduro Biotech (NASDAQ:ADRO)
Price Target History for Aduro Biotech (NASDAQ:ADRO)
Analysts' Ratings History for Aduro Biotech (NASDAQ:ADRO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017HC WainwrightSet Price TargetBuy$18.00N/AView Rating Details
10/2/2017William BlairReiterated RatingOutperformHighView Rating Details
8/3/2017Canaccord GenuitySet Price TargetBuy$30.00LowView Rating Details
7/18/2017Cowen and CompanyInitiated CoverageOutperformLowView Rating Details
5/1/2017Rodman & RenshawInitiated CoverageBuy -> Buy$18.00LowView Rating Details
3/7/2017FBR & CoReiterated RatingBuy$23.00N/AView Rating Details
3/7/2017Roth CapitalReiterated RatingBuy$17.00N/AView Rating Details
10/24/2016Leerink SwannSet Price TargetBuy$14.00N/AView Rating Details
3/15/2016Bank of America CorporationDowngradeBuy -> Underperform$32.00 -> $14.00N/AView Rating Details
12/1/2015Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Aduro Biotech (NASDAQ:ADRO)
Earnings by Quarter for Aduro Biotech (NASDAQ:ADRO)
Earnings History by Quarter for Aduro Biotech (NASDAQ ADRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.25)($0.27)$3.98 million$5.90 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.39)($0.32)$3.74 million$3.77 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.40)($0.44)$3.83 million$3.88 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.45)($0.54)$3.99 million$3.79 millionViewN/AView Earnings Details
8/3/2016Q2 2016($0.18)$0.03$25.24 million$39.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.25)($0.45)$13.47 million$4.03 millionViewN/AView Earnings Details
3/8/2016Q415($0.15)$0.04$17.55 million$34.38 millionViewN/AView Earnings Details
11/23/2015Q3($0.08)$0.01$15.80 million$19.15 millionViewN/AView Earnings Details
8/10/2015Q215($0.01)($0.18)$1.00 million$9.90 millionViewN/AView Earnings Details
5/28/2015Q115($0.08)($39.97)$12.03 million$9.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aduro Biotech (NASDAQ:ADRO)
2017 EPS Consensus Estimate: ($1.52)
2018 EPS Consensus Estimate: ($1.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.39)($0.35)($0.38)
Q2 20173($0.41)($0.31)($0.38)
Q3 20173($0.43)($0.30)($0.38)
Q4 20173($0.50)($0.32)($0.38)
Q1 20182($0.37)($0.24)($0.31)
Q2 20182($0.41)($0.19)($0.30)
Q3 20182($0.45)($0.20)($0.33)
Q4 20182($0.45)($0.21)($0.33)
(Data provided by Zacks Investment Research)


Dividend History for Aduro Biotech (NASDAQ:ADRO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Aduro Biotech (NASDAQ:ADRO)
Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 35.05%
Insider Trades by Quarter for Aduro Biotech (NASDAQ:ADRO)
Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)
Insider Trades by Quarter for Aduro Biotech (NASDAQ:ADRO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Dirk G BrockstedtEVPSell10,000$10.59$105,900.00View SEC Filing  
10/2/2017Gregory W SchaferCOOSell20,000$10.75$215,000.00View SEC Filing  
10/2/2017Jennifer LewInsiderSell6,600$10.61$70,026.00View SEC Filing  
10/2/2017Stephen T IsaacsCEOSell40,000$10.78$431,200.00View SEC Filing  
9/18/2017Blaine TemplemanVPSell2,884$11.20$32,300.80View SEC Filing  
9/13/2017Blaine TemplemanVPSell3,557$10.99$39,091.43View SEC Filing  
9/13/2017Elsas Andrea VanInsiderSell4,922$10.99$54,092.78View SEC Filing  
9/13/2017Gregory W SchaferCOOSell4,859$10.99$53,400.41View SEC Filing  
9/1/2017Dirk G BrockstedtEVPSell10,000$11.69$116,900.00View SEC Filing  
9/1/2017Gregory W SchaferCOOSell20,000$11.70$234,000.00View SEC Filing  
9/1/2017Jennifer LewInsiderSell6,600$11.70$77,220.00View SEC Filing  
8/11/2017Thomas W DubenskyInsiderSell50,000$11.38$569,000.00View SEC Filing  
8/10/2017Thomas W DubenskyInsiderSell40,912$11.43$467,624.16View SEC Filing  
8/8/2017Gregory W SchaferCOOSell40,000$12.17$486,800.00View SEC Filing  
8/7/2017Dirk G BrockstedtEVPSell10,000$12.18$121,800.00View SEC Filing  
8/7/2017Gregory W SchaferCOOSell25,811$12.17$314,119.87View SEC Filing  
8/7/2017Jennifer LewInsiderSell6,600$12.17$80,322.00View SEC Filing  
8/7/2017Stephen T IsaacsCEOSell40,000$12.19$487,600.00View SEC Filing  
7/6/2017Thomas W DubenskyInsiderSell50,000$11.33$566,500.00View SEC Filing  
7/5/2017Stephen T IsaacsInsiderSell40,000$11.06$442,400.00View SEC Filing  
7/3/2017Dirk G BrockstedtEVPSell10,000$11.02$110,200.00View SEC Filing  
7/3/2017Jennifer LewInsiderSell12,000$11.14$133,680.00View SEC Filing  
6/28/2017Gregory W SchaferCOOSell40,000$11.26$450,400.00View SEC Filing  
6/28/2017Jennifer LewInsiderSell12,000$11.19$134,280.00View SEC Filing  
6/19/2017Stephen T IsaacsInsiderSell40,000$10.50$420,000.00View SEC Filing  
6/5/2017Thomas W DubenskyInsiderSell144,301$10.03$1,447,339.03View SEC Filing  
5/17/2017Blaine TemplemanVPSell1,648$9.65$15,903.20View SEC Filing  
5/17/2017Dirk G. BrockstedtEVPSell1,011$9.65$9,756.15View SEC Filing  
5/16/2017Stephen T. IsaacsCEOSell16,673$10.00$166,730.00View SEC Filing  
5/16/2017Stephen T. IsaacsinsiderSell27,273$10.01$273,002.73View SEC Filing  
5/15/2017Stephen T. IsaacsCEOSell10,600$10.01$106,106.00View SEC Filing  
5/12/2017Thomas W DubenskyInsiderSell5,699$9.92$56,534.08View SEC Filing  
5/11/2017Dirk G BrockstedtEVPSell8,000$9.72$77,760.00View SEC Filing  
4/3/2017Dirk G BrockstedtEVPSell8,000$10.71$85,680.00View SEC Filing  
4/3/2017Stephen T IsaacsInsiderSell27,273$10.28$280,366.44View SEC Filing  
3/13/2017Stephen T IsaacsInsiderSell27,273$11.35$309,548.55View SEC Filing  
3/9/2017Dirk G BrockstedtEVPSell8,000$11.00$88,000.00View SEC Filing  
3/9/2017Thomas W DubenskyInsiderSell25,000$10.96$274,000.00View SEC Filing  
1/17/2017Dirk G BrockstedtEVPSell8,000$11.86$94,880.00View SEC Filing  
1/11/2017Blaine TemplemanVPSell3,785$11.95$45,230.75View SEC Filing  
1/3/2017Stephen T IsaacsInsiderSell27,273$11.12$303,275.76View SEC Filing  
12/1/2016Thomas W DubenskyInsiderSell25,000$10.94$273,500.00View SEC Filing  
11/14/2016Ross HaghighatDirectorSell7,088$15.50$109,864.00View SEC Filing  
10/3/2016Stephen T IsaacsCEOSell27,273$12.67$345,548.91View SEC Filing  
10/3/2016Thomas W DubenskyInsiderSell25,000$12.68$317,000.00View SEC Filing  
9/19/2016Jennifer LewInsiderSell6,360$14.95$95,082.00View SEC Filing  
9/1/2016Thomas W DubenskyInsiderSell25,000$14.03$350,750.00View SEC Filing  
8/11/2016Thomas W DubenskyInsiderSell25,000$15.18$379,500.00View SEC Filing  
7/5/2016Thomas W DubenskyInsiderSell25,000$11.61$290,250.00View SEC Filing  
5/16/2016Thomas W. DubenskyInsiderSell905$8.20$7,421.00View SEC Filing  
1/11/2016Dirk G. BrockstedtVPSell22,000$21.77$478,940.00View SEC Filing  
1/8/2016Gregory W. SchaferCOOSell20,000$23.58$471,600.00View SEC Filing  
1/6/2016Jennifer LewVPSell5,242$25.71$134,771.82View SEC Filing  
1/5/2016Stephen T. IsaacsCEOSell25,000$26.31$657,750.00View SEC Filing  
1/4/2016Thomas W. DubenskyinsiderSell15,000$26.37$395,550.00View SEC Filing  
12/7/2015Gregory W. SchaferCOOSell25,000$29.74$743,500.00View SEC Filing  
12/3/2015Jennifer LewVPSell5,242$29.85$156,473.70View SEC Filing  
12/1/2015Stephen T. IsaacsCEOSell25,000$29.11$727,750.00View SEC Filing  
12/1/2015Thomas W. DubenskyinsiderSell30,000$29.27$878,100.00View SEC Filing  
11/18/2015Jennifer LewVPSell6,712$28.52$191,426.24View SEC Filing  
11/17/2015Gregory W. SchaferCOOSell26,470$28.15$745,130.50View SEC Filing  
11/17/2015Thomas W. DubenskyinsiderSell31,470$28.27$889,656.90View SEC Filing  
11/16/2015Stephen T. IsaacsCEOSell25,000$27.54$688,500.00View SEC Filing  
4/20/2015Jennifer LewVPBuy2,000$17.00$34,000.00View SEC Filing  
4/20/2015Venture (Vi) Inves MorningsideMajor ShareholderBuy441,176$17.00$7,499,992.00View SEC Filing  
4/20/2015William Mariner GreenmanDirectorBuy3,000$17.00$51,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aduro Biotech (NASDAQ:ADRO)
Latest Headlines for Aduro Biotech (NASDAQ:ADRO)
DateHeadline logoAduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on ... - GlobeNewswire (press release) - October 17 at 9:11 PM logoAduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on Lung Cancer - October 17 at 4:08 PM logoAdverum Biotechnologies (ADVM) in Focus: Stock Moves 9.7% Higher - October 13 at 3:26 PM logoAduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer's 32nd Annual ... - GlobeNewswire (press release) - October 9 at 9:39 PM logoAduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting - October 9 at 4:38 PM logoLigand (LGND) Signs Deal to Acquire Crystal Bioscience - October 5 at 12:27 PM logoJennifer Lew Sells 6,600 Shares of Aduro Biotech, Inc. (ADRO) Stock - October 4 at 10:42 PM logoDirk G. Brockstedt Sells 10,000 Shares of Aduro Biotech, Inc. (ADRO) Stock - October 4 at 10:24 PM logoInsider Selling: Aduro Biotech, Inc. (ADRO) COO Sells 20,000 Shares of Stock - October 4 at 10:22 PM logoInsider Selling: Aduro Biotech, Inc. (ADRO) CEO Sells 40,000 Shares of Stock - October 4 at 10:22 PM logoAduro Biotech, Inc. (ADRO) Receives Outperform Rating from William Blair - October 2 at 11:24 AM logoAduro Biotech, Inc. (ADRO) Receives Average Recommendation of "Buy" from Analysts - September 30 at 8:52 AM logoAduro Biotech (ADRO) Reports First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD - - September 29 at 3:10 PM logoTrial has begun in Patients with Metastatic Colorectal Cancer Who Have Few Treatment Options - September 28 at 1:37 AM logoAduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas - September 28 at 1:37 AM logoAduro Biotech (ADRO) Reports First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD - September 28 at 1:37 AM logoAduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology - September 28 at 1:37 AM logoHC Wainwright Reaffirms Buy Rating for Aduro Biotech, Inc. (ADRO) - September 27 at 7:28 PM logoCommit To Buy Aduro Biotech At $10, Earn 24.2% Annualized Using Options - September 22 at 2:59 PM logoInsider Selling: Aduro Biotech, Inc. (ADRO) VP Sells 2,884 Shares of Stock - September 20 at 8:46 PM logoAduro Biotech to Present at Three Investor Conferences in the Second Half of September - September 18 at 9:01 PM logo Analysts Expect Aduro Biotech, Inc. (ADRO) Will Post Quarterly Sales of $4.18 Million - September 15 at 11:20 AM logoAduro Biotech, Inc. (ADRO) Insider Elsas Andrea Van Sells 4,922 Shares - September 14 at 11:56 PM logoBlaine Templeman Sells 3,557 Shares of Aduro Biotech, Inc. (ADRO) Stock - September 14 at 11:56 PM logoAduro Biotech, Inc. (ADRO) COO Gregory W. Schafer Sells 4,859 Shares - September 14 at 11:56 PM logoAduro Biotech (ADRO) and Catalyst Pharmaceuticals (CPRX) Head-To-Head Survey - September 12 at 2:32 PM logoWhy Is Aduro Biotech (ADRO) Down 6.8% Since the Last Earnings Report? - Nasdaq - September 8 at 3:49 PM logoWhy Is Aduro Biotech (ADRO) Down 6.8% Since the Last Earnings Report? - September 8 at 3:49 PM logoETFs with exposure to Aduro BioTech, Inc. : September 7, 2017 - September 7 at 3:29 PM logoVIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug ... - Nasdaq - September 7 at 1:31 AM logoAduro Biotech, Inc. (ADRO) Insider Jennifer Lew Sells 6,600 Shares - September 6 at 9:16 PM logoNovartis' (NVS) MS Drug Gilenya Positive in Long-Term Study - September 6 at 3:27 PM logoAduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017 - September 6 at 3:27 PM logoAduro Biotech, Inc. (ADRO) Receives Consensus Rating of "Buy" from Brokerages - September 5 at 8:55 AM logoAduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : September 1, 2017 - September 1 at 4:07 PM logoThe Medicines Company's Infection Drug Vabomere Gets FDA Nod - September 1 at 1:21 AM logoAduro Biotech to Present at Three Investor Conferences in the First Half of September - September 1 at 1:21 AM logoNovo Nordisk's Tresiba Gets Canadian Nod - August 30 at 1:53 AM logoKamada (KMDA) Gets FDA Approval for Rabies Vaccine - Nasdaq - August 28 at 3:36 PM logoWeek In Review: Columbia China Building $150 Million Hospital In Jiaxing - Seeking Alpha - August 27 at 3:22 PM logoAduro Biotech: Buy, Sell Or Hold? - August 26 at 8:23 PM logoWill Endo (ENDP) Continue to Disappoint Investors in 2017? - Nasdaq - August 25 at 10:09 PM logoAduro BioTech, Inc. – Value Analysis (NASDAQ:ADRO) : August 23, 2017 - August 23 at 8:35 PM logoAlexion's (ALXN) Soliris' Label Expansion Approved in Europe - Nasdaq - August 22 at 4:01 PM logoHead-To-Head Comparison: Aduro Biotech (ADRO) vs. Prothena Corporation PLC (PRTA) - August 20 at 6:20 PM logoMallinckrodt (MNK) Looks Strong on Acthar, Generics Weak - Nasdaq - Nasdaq - August 15 at 9:00 PM logoAduro Biotech, Inc. (NASDAQ:ADRO) Insider Thomas W. Dubensky Sells 40,912 Shares - August 11 at 10:36 PM logoAduro Biotech, Inc. (NASDAQ:ADRO) Insider Thomas W. Dubensky Sells 50,000 Shares - August 11 at 10:36 PM logoAduro BioTech, Inc. breached its 50 day moving average in a Bearish Manner : ADRO-US : August 11, 2017 - August 11 at 3:59 PM logoAduro Biotech, Inc. (NASDAQ:ADRO) Given Average Rating of "Buy" by Analysts - August 11 at 8:42 AM



Aduro Biotech (ADRO) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.